Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS/TOP PLAYER POSITIONING, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

Chapter: 4 SEASONAL INFLUENZA VACCINE MARKET, BY PRODUCT TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. TYPE A (H1N1)

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. TYPE A (H3N2)

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. TYPE B

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

Chapter: 5 SEASONAL INFLUENZA VACCINE MARKET, BY AGE GROUP

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. PEDIATRICS

5.2.1. Key market trends

5.3. ADOLESCENCE

5.3.1. Key market trends

5.4. ADULTS

5.4.1. Key market trends

5.5. ELDERLY

5.5.1. Key market trends

Chapter: 6 SEASONAL INFLUENZA VACCINE MARKET, BY REGION

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.2.4. North America Seasonal Influenza Vaccine Market by Product Type
6.2.5. North America Seasonal Influenza Vaccine Market by End User

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Spain market size and forecast
6.3.3.5. Rest of Europe market size and forecast

6.3.4. Europe Seasonal Influenza Vaccine Market by Product Type
6.3.5. Europe Seasonal Influenza Vaccine Market by End User

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. Rest of Asia-Pacific market size and forecast

6.4.4. Asia-Pacific Seasonal Influenza Vaccine Market by Product Type
6.4.5. Asia-Pacific Seasonal Influenza Vaccine Market by End User

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Brazil market size and forecast
6.5.3.2. Turkey market size and forecast
6.5.3.3. Saudi Arabia market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Rest of LAMEA market size and forecast

6.5.4. LAMEA Seasonal Influenza Vaccine Market by Product Type
6.5.5. LAMEA Seasonal Influenza Vaccine Market by End User

Chapter: 7 COMPANY PROFILES

7.1. GLAXOSMITHKLINE PLC

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. SINOVAC BIOTECH LTD.

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. CHANGSHENG BIO-TECHNOLOGY CO., LTD.

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. CCBIO SA

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. ALEPH BIOMEDICAL

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. SANOFI S.A.

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. JIANGSU SIMCERE VAXTEC BIO-PHARMACEUTICAL CO., LTD.

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. DALIAN HISSEN BIO-PHARM

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments

7.9. ABBOTT LABORATORIES

7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments

7.10. NOVARTIS INTERNATIONAL AG

7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments